Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300).


Journal

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
ISSN: 1724-191X
Titre abrégé: Phys Med
Pays: Italy
ID NLM: 9302888

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 16 01 2020
revised: 03 07 2020
accepted: 09 07 2020
pubmed: 5 8 2020
medline: 25 6 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

The aim was to evaluate dosimetric uncertainties of a mixed beam approach for patients with high-risk prostate cancer (PCa). The treatment consists of a carbon ion radiotherapy (CIRT) boost followed by whole-pelvis intensity-modulated RT (IMRT). Patients were treated with a CIRT boost of 16.6 Gy/4 fractions followed by whole-pelvis IMRT of 50 Gy/25 fractions, with consequent long term androgen deprivation therapy. Deformable computed tomography image registration (DIR) was performed and corresponding doses were used for plan sum. A comparative IMRT photon plan was obtained as whole-pelvis IMRT of 50 Gy/25 fractions followed by a boost of 28 Gy/14 fractions. DIR performances were evaluated through structure-related and image characteristics parameters. Until now, five patients out of ten total enrolled ended the treatment. Dosimetric parameters were lower in CIRT + IMRT than IMRT-only plans for all organs at risk (OARs) except femoral heads. Regarding DIR evaluation, femoral heads were the less deformed OAR. Penile bulb, bladder and anal canal showed intermediate deformation. Rectum was the most deformed. DIR algorithms were patient (P)-dependent, as performances were the highest for P3 and P4, intermediate for P2 and P5, and the lowest for P1. CIRT allows better OARs sparing while increasing the efficacy due to the higher radio-biological effect of carbon ions. However, a mixed beam approach could introduce DIR problems in multi-centric treatments with different operative protocols. The development of this prospective trial will lead to more mature data concerning the clinical impact of implementing DIR procedures in dose accumulation applications for high-risk PCa treatments.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
The aim was to evaluate dosimetric uncertainties of a mixed beam approach for patients with high-risk prostate cancer (PCa). The treatment consists of a carbon ion radiotherapy (CIRT) boost followed by whole-pelvis intensity-modulated RT (IMRT).
MATERIALS AND METHODS METHODS
Patients were treated with a CIRT boost of 16.6 Gy/4 fractions followed by whole-pelvis IMRT of 50 Gy/25 fractions, with consequent long term androgen deprivation therapy. Deformable computed tomography image registration (DIR) was performed and corresponding doses were used for plan sum. A comparative IMRT photon plan was obtained as whole-pelvis IMRT of 50 Gy/25 fractions followed by a boost of 28 Gy/14 fractions. DIR performances were evaluated through structure-related and image characteristics parameters.
RESULTS RESULTS
Until now, five patients out of ten total enrolled ended the treatment. Dosimetric parameters were lower in CIRT + IMRT than IMRT-only plans for all organs at risk (OARs) except femoral heads. Regarding DIR evaluation, femoral heads were the less deformed OAR. Penile bulb, bladder and anal canal showed intermediate deformation. Rectum was the most deformed. DIR algorithms were patient (P)-dependent, as performances were the highest for P3 and P4, intermediate for P2 and P5, and the lowest for P1.
CONCLUSIONS CONCLUSIONS
CIRT allows better OARs sparing while increasing the efficacy due to the higher radio-biological effect of carbon ions. However, a mixed beam approach could introduce DIR problems in multi-centric treatments with different operative protocols. The development of this prospective trial will lead to more mature data concerning the clinical impact of implementing DIR procedures in dose accumulation applications for high-risk PCa treatments.

Identifiants

pubmed: 32750548
pii: S1120-1797(20)30172-1
doi: 10.1016/j.ejmp.2020.07.012
pii:
doi:

Substances chimiques

Androgen Antagonists 0
Ions 0
Carbon 7440-44-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

327-336

Informations de copyright

Copyright © 2020 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Simone Giovanni Gugliandolo (SG)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Giulia Marvaso (G)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.

Stefania Comi (S)

Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Matteo Pepa (M)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: matteo.pepa@ieo.it.

Chiara Romanò (C)

Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Dario Zerini (D)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Matteo Augugliaro (M)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Stefania Russo (S)

Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Str. Campeggi, 53, 27100, Pavia, Italy.

Barbara Vischioni (B)

Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Str. Campeggi, 53, 27100, Pavia, Italy.

Francesca Valvo (F)

Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Str. Campeggi, 53, 27100, Pavia, Italy.

Tommaso Giandini (T)

Unit of Medical Physics, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milano, Italy.

Barbara Avuzzi (B)

Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milano, Italy.

Riccardo Valdagni (R)

Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.

Delia Ciardo (D)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Ottavio De Cobelli (O)

Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy; Division of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.

Federica Cattani (F)

Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Roberto Orecchia (R)

Scientific Directorate, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH